The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Sequencing CAR T-cell therapy and bispecific antibodies in relapsed follicular lymphoma
Marco Ladetto, MD, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, discusses treatment sequencing for patients with high-risk or relapsed follicular lymphoma. He reviews the roles of CAR T-cell therapy and bispecific antibodies, emphasizing the importance of individualized decision-making and highlighting the growing range of therapeutic options available for patients who experience multiple relapses. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
